Curanex Pharmaceuticals Completes GMP Manufacturing Milestone for Ulcerative Colitis Drug Candidate Phyto-N
Key Insights
Curanex Pharmaceuticals (search) completed a Good Manufacturing Practice (GMP)-compliant pilot-scale batch of its lead botanical drug candidate, Phyto-N (search), for ulcerative colitis (search) treatment.
The GMP batch will support GLP-compliant toxicology and pharmacokinetic studies ahead of a planned Investigational New Drug submission targeted for Q4 2026.
Non-GLP toxicity studies in rats and dogs showed no treatment-related adverse effects, supporting the drug's safety profile for clinical development.
Curanex Pharmaceuticals (search) Inc. announced Wednesday the completion of a Good Manufacturing Practice (GMP)-compliant pilot-scale batch of its lead botanical drug candidate, Phyto-N (search), marking a critical manufacturing milestone in the company's path toward clinical development for ulcerative colitis (search) treatment.
The New York-based pharmaceutical company stated that the GMP batch will support GLP-compliant toxicology and pharmacokinetic studies ahead of a planned Investigational New Drug (IND) submission for ulcerative colitis (search), targeted for the fourth quarter of 2026. Ulcerative colitis is a chronic inflammatory bowel disease (search) affecting approximately 5 million patients worldwide.
Manufacturing and Regulatory Progress
CEO Jun Liu emphasized the significance of this achievement, stating, "This has been a successful, critical next step as we prepare our first IND submission for FDA review." The completion of GMP manufacturing represents a crucial regulatory requirement for advancing botanical drug candidates toward human clinical trials.
Dr. Liqin Xie, Curanex's chief operating officer, confirmed the company is advancing GLP toxicology and pharmacokinetic studies, with clinical development to follow, including planned trials in Australia. This international approach suggests the company is preparing for a comprehensive clinical development program.
Preclinical Safety Profile
Supporting the drug's development trajectory, Curanex Pharmaceuticals (search) reported that non-GLP toxicity studies in rats and dogs showed no treatment-related adverse effects. This preclinical safety data provides important foundational evidence as the company prepares for more rigorous GLP studies required for regulatory submissions.
The botanical nature of Phyto-N (search) represents an interesting approach to treating inflammatory bowel disease (search), as botanical drugs must meet specific FDA requirements that differ from traditional synthetic pharmaceuticals, including standardized manufacturing processes and comprehensive characterization of active components.
Market Response and Company Status
The manufacturing milestone drove significant investor interest, with Curanex shares rising 56.32% in after-hours trading to $0.49 on Wednesday. The development-stage biotechnology company, which completed its initial public offering in August 2025, currently maintains a market capitalization of $8.73 million.
Despite the positive reaction to the manufacturing news, the company's stock has experienced significant volatility, falling 92.15% over the past 12 months, with a 52-week high of $9.18 and a 52-week low of $0.27. The stock closed its regular session up 4.26% at $0.32 before the after-hours surge.